Molecular Partners Ag  (MOLN)
Other Ticker:  
Price: $3.8800 $0.56 16.867%
Day's High: $3.89 Week Perf: -1.77 %
Day's Low: $ 3.72 30 Day Perf: -2.87 %
Volume (M): 4 52 Wk High: $ 7.32
Volume (M$): $ 14 52 Wk Avg: $5.06
Open: $3.72 52 Wk Low: $3.32

 Market Capitalization (Millions $) 127
 Shares Outstanding (Millions) 33
 Employees -
 Revenues (TTM) (Millions $) 7
 Net Income (TTM) (Millions $) -62
 Cash Flow (TTM) (Millions $) 88
 Capital Exp. (TTM) (Millions $) 1

Molecular Partners Ag
Molecular Partners AG is a biopharmaceutical company based in Switzerland. The company specializes in the discovery, development, and commercialization of innovative therapeutic proteins known as DARPins (Designed Ankyrin Repeat Proteins). These proteins are designed to target and inhibit disease-causing molecules, such as cancer cells or inflammatory factors.

Molecular Partners AG has a diverse pipeline of therapeutic candidates, with a focus on oncology, ophthalmology, and infectious diseases. The company has partnerships with several pharmaceutical companies, including Amgen, Allergan, and Novartis, to develop and commercialize its products.

The company's most advanced product candidate, MP0250, is being developed for the treatment of solid tumors and is currently in clinical trials. Molecular Partners AG also has a proprietary platform called DARPin X-Target, which allows for the discovery and development of DARPins that target specific disease-related molecules, enabling a more targeted and effective treatment approach.

Overall, Molecular Partners AG is committed to advancing the field of biopharmaceuticals and developing innovative therapies that have the potential to address unmet medical needs and improve patient outcomes.

   Company Address: Wagistrasse 14 Zurich-Schlieren 8952
   Company Phone Number: 44 755 77 00   Stock Exchange / Ticker: NASDAQ MOLN


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Molecular Partners Ag

Headline: Financial Crisis Strikes Molecular Partners Ag with Massive Revenue Decline in Q4 2023

The Biotechnology & Pharmaceuticals company, Molecular Partners Ag, has recently reported a disastrous fourth quarter of 2023 financial report that has sent shockwaves through the industry. The company's revenue faded by a staggering -96.288%, plummeting to just $7.04 million. This is a significant decline from the corresponding reporting season a year ago, where the company had reported a much healthier revenue. Additionally, the net loss per share has swelled to an alarming $-1.89, compared to the previous year's figure of $0.00 per share.
For the financial fourth quarter of 2023, Molecular Partners Ag recorded a net loss of $-61.984 million, a complete reversal from the net proceeds of $117.853 million seen in the corresponding reporting season a year before. These alarming figures suggest that the company is experiencing significant financial turmoil and struggling to generate profits.
Throughout the fiscal year 2023, Molecular Partners Ag delivered a net loss of $-61.98 million, further highlighting its worsening financial situation. The company's revenue for the same period was a meager $7.04 million, a far cry from its previous fiscal year's revenue. This represents a decline of -96.29% from the previous year, where the company had reported an impressive revenue of $189.60 million.
The company's earnings per share (EPS) also suffered a significant blow, declining from $3.54 in the previous fiscal year to a dismal $-1.89 for 2023. This further emphasizes the company's poor financial performance and raises concerns about its ability to recover.
The drastic decline in Molecular Partners Ag's financials is alarming and raises questions about its future prospects. The disappointing figures indicate a lack of profitability and a severe decline in revenue generation, which will undoubtedly impact the company's growth strategy going forward.
Furthermore, it is important to note that Molecular Partners Ag has recently announced a strategic collaboration with Orano Med to co-develop Radio-DARPin therapeutics (RDTs) for cancer treatment. While this partnership holds promise for revolutionizing cancer treatments, there is no guarantee that it will successfully turn the company's fortunes around.
The market has not responded positively to Molecular Partners Ag's financial report, as the stock price has remained stagnant. Year-to-date performance is at a dismal 0%, indicating a lack of investor confidence in the company's ability to bounce back. Additionally, the stock is trading only 18.1% above its 52-week low, suggesting further downside potential.


Molecular Partners and Orano Med: Blasting Cancer Cells with Radio-DARPin Therapies

Published Fri, Jan 5 2024 9:00 PM UTC

Molecular Partners and Orano Med Team Up to Develop Cutting-Edge Radio-DARPin Therapies to Combat CancerZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., and PARIS, Jan. 05, 2024 - In a significant move towards innovative cancer treatments, Molecular Partners AG and Orano Med have announced a strategic collaboration to co-develop Radio-DARPin therapeutics (RDTs). Molecular P...


Molecular Partners Ag's Segments
• View Complete Report
  Company Estimates  
  Revenue Outlook
Molecular Partners Ag does not provide revenue guidance.

Earnings Outlook
Molecular Partners Ag does not provide earnings estimates.

Geographic Revenue Dispersion


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com